Open Access. Powered by Scholars. Published by Universities.®
Cell and Developmental Biology Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Cell and Developmental Biology
Inhibition Of Dna Methylation In Acquired Tamoxifen-Resistant Breast Cancer: Cell Line Model And Clinical Implications, Stephanie Zimmers
Inhibition Of Dna Methylation In Acquired Tamoxifen-Resistant Breast Cancer: Cell Line Model And Clinical Implications, Stephanie Zimmers
Doctoral Dissertations
One out of every eight American women will develop invasive breast cancer throughout their lifetime. Approximately 70% of breast cancers are estrogen receptor alpha (ER)-positive and can therefore be treated with an anti-estrogen such as tamoxifen. Although tamoxifen treatment has been successful at reducing breast cancer death rates, nearly one-third of women treated with tamoxifen for 5 years will have disease recurrence. Therefore, it is imperative that researchers investigate the mechanisms involved in developing acquired tamoxifen resistance and identify biomarkers that are predictive of acquired resistance. DNA methylation is known to play a role in the development of breast cancer …
Dna-Based Epigenetic Changes In Recurrent And Tamoxifen-Resistant Breast Cancer, Kristin E. Williams
Dna-Based Epigenetic Changes In Recurrent And Tamoxifen-Resistant Breast Cancer, Kristin E. Williams
Doctoral Dissertations
Roughly two-thirds of all breast cancers are Estrogen Receptor a (ER)-positive and can be treated with an anti-estrogen such as Tamoxifen, however resistance occurs in 33% of women who take the drug for more than 5 years. In addition to this acquired antiestrogen resistance, de novo- or intrinsic-resistance occurs primarily in ER-negative tumors but also occasionally in ER-positive tumors. Aberrant DNA promoter methylation, a major epigenetic mechanism by which gene expression is altered in cancer, is thought to play a role in this resistance. To date, few studies have examined promoter methylation and Tamoxifen resistance in breast cancer. Of the …